Table 4.
Rank probability or Surface Under the Cumulative Ranking (SUCRA) values for interventions.
| P-A | N-I | Ave-A | N-C | P-L | S | Inference | |
|---|---|---|---|---|---|---|---|
| aOverall survival (%) | 40.2 | 19.7 | — | 25.3 | 14.9 | 0.0 | P-A>N-C>N-I>P-L>S |
| aProgression-free survival (%) | 8.4 | 5.3 | 8.1 | 21.1 | 57.1 | 0.0 | P-L>N-C>P-A=Ave-A>N-I>S |
| bObjrctive response rate (%) | 45.3 | 22.0 | 62.7 | 74.1 | 95.8 | 0.0 | P-L>N-C>Ave-A>P-A>N-I>S |
| bComplete response (%) | 60.2 | 96.1 | 34.5 | 32.2 | 75.0 | 2.1 | N-I>P-L>P-A>Ave-A=N-C>S |
| bPartial response (%) | 47.8 | 20.0 | 80.5 | 86.7 | 64.7 | 0.3 | N-C=Ave-A>P-L>P-A>N-I>S |
| bOverall adverse events (%) | 87.8 | 85.5 | 39.9 | 23.9 | 13.1 | 49.9 | P-A=N-I>S>Ave-A>N-C>P-L |
| bAdverse events ≥3 (%) | 30.5 | 100.0 | 66.1 | 33.9 | 3.0 | 66.4 | N-I>S=Ave-A>N-C=P-A>P-L |
P-A, Pembrolizumab-Axitinib; N-I, Nivolumab-Ipilimumab; Ave-A, Avelumab-Axitinib; N-C, Nivolumab-Cabozantinib; P-L, Pembrolizumab-Lenvatinib; S, Sunitinib.
a
Preferred rank probabilities of interventions for study endpoints.
b
SUCRA of interventions for study endpoints.